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We conducted the first prospective non-randomized single institution study to evaluate Agatston coronary calcium scoring (CCS) by CCT with concomitant coronary CT angiograms (CCTA) as a tool to identify the survivors at risk for CV disease. Twenty asymptomatic post allo-SCT survivors underwent CCS and contrast enhanced CCTA at a median follow up of 6 years post transplant. Patient characteristics are shown in Table 1 . Ten-year Framingham CV risk scores (FRS) were also calculated at the time of screening. Subjects were prepared for coronary CTA according to standard guidelines. 8 Non-obstructive CAD was detected in eight (45%) patients, and obstructive CAD in one (5%). Two (22.2%) of these had single vessel disease, three (33.3%) had two vessel disease and four (44.5%) had triple vessel disease. Additionally, five (55.5%) of these subjects had aortic root calcification. Lesion distributions by arterial territory were as follows: left main 8.7%, left anterior descending 35%, left circumflex 26% and right coronary artery 30.4%. Characteristics of coronary plaques were as follows: 48% calcified, 48% mixed calcified/non-calcified and 4% non-calcified. In those with CAD, the median CCS was 55 (range: 0-5110; Po0.001), corresponding to the 75th percentile (range: 33rd-99th percentile; Po0.001) adjusted for age, gender and ethnicity. In comparison, those with no CAD had a median CCS of 0, o1 percentile. One patient with o1% FRS had a zero CCS with nonobstructive CAD (mixed plaque) on the CCTA. The radiation exposure during the procedure was acceptable, at a median of 0.78 mSv (range 0.18-3.12 mSv) for the CCS and 1.15 mSv (range 0-8.01) for the CCTA. There were no complications related to the procedure.
Standard cardiac risk factors are used by FRS to determine the 10-year risk of developing CV disease in an individual with no known CV disease. It is well established that CCS adds independent prognostic information to that obtained by FRS. 10 However in this group of post allo-SCT survivors we detected CAD in 4 of 15 (26.6%) patients who would be considered 'low risk' by conventional FRS stratification. This suggests a potential role for screening all patients post allo-SCT, regardless of FRS. CCS alone (sensitivity of 89% and specificity of 100%, in this preliminary study) may be adequate for screening and avoids the use of i.v. contrast.
We conclude that CCS with or without CCTA is a safe, feasible, potentially sensitive method to evaluate CV risk in asymptomatic low FRS transplant survivors. Such individuals may benefit by earlier intervention to prevent CV events. Factors contributing to increased CV risk detected by this sensitive approach will now be explored in a larger patient cohort. 
